Who is sponsoring NCT02173886?

NCT02173886 is sponsored by North Dakota State University.

What condition does NCT02173886 study?

NCT02173886 studies Roux en Y Gastric Bypass.

What drugs are being tested in NCT02173886?

Interventions: Bupropion SR and XL.

What is the status of NCT02173886?

NCT02173886 is currently COMPLETED.

Last reviewed 2016-09-26 · How we verify

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

NCT02173886 Phase 4 COMPLETED

This study is being conducted to evaluate how the body absorbs and processes the sustained release (SR) and extended release (XL) medication bupropion (Wellbutrin®). Subject who are 1-3 years post gastric bypass surgery will be invited to participate. Non-surgical controls will also be enrolled based on a matching criteria to post gastric bypass subjects. Participants will be asked to complete two 12-hour study days approximately 11 days apart.

Details

Lead sponsor	North Dakota State University
Phase	Phase 4
Status	COMPLETED
Enrolment	20
Start date	2014-06
Completion	2015-02

Conditions

Roux en Y Gastric Bypass

Interventions

Bupropion SR and XL

Primary outcomes

Bupropion Plasma Concentrations/Area-Under-the-Curve (AUC) — 48 hours intervals
The primary aim of this research is to provide a comparison of pharmacokinetic measures associated with a single dose of bupropion SR (sustained release) and bupropion XL (extended release) in Roux-en-Y Gastric Bypass and matched nonsurgical "control" subjects. Comparisons will be based upon bupropion plasma concentrations obtained during the 48 hour sample collection window.

Countries

United States